Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Porch Group Q3 2025 Earnings Call - Surplus Soars $100M, Ushering Path to $70M Adjusted EBITDA and $2B Premium Potential
Porch Group's Q3 2025 earnings call reveals a company firing on all cylinders, exceeding its adjusted EBITDA target with $21 million in the quarter and $53.1 million year-to-date, poised to reach $70 ...
- Porch Group delivered $21 million adjusted EBITDA in Q3 2025, bringing year-to-date adjusted EBITDA to $53.1 million, surpassing the initial $50 million full-year target.
- The company raised its full-year adjusted EBITDA guidance to $70 million, representing a 10 times improvement from the prior year.
- Reciprocal insurance business surplus (including non-admitted assets) surged by over $100 million quarter-over-quarter to $412 million, doubling surplus in six months.
- +9 more takeaways
OraSure Technologies 2025 Q3 Earnings Call - Transitioning 2025 with Strategic Acquisitions and Innovation Towards 2026 Growth
OraSure Technologies reported $27.1 million in total revenue for Q3 2025, with international diagnostics and sample management presenting mixed results amid challenging funding environments and govern...
- OraSure reported $27.1 million total revenue in Q3 2025, with diagnostics at $14.5 million and sample management at $10.3 million.
- International diagnostics revenue expected to decline about 20% in 2025 versus 2024 due to funding and inventory cycles.
- The company signed a definitive agreement to acquire Biomedomics, adding the SickleScan rapid test for sickle cell disease primarily targeting underserved international markets.
- +9 more takeaways
eHealth Inc. Q3 2025 Earnings Call - CEO Focuses on AEP Execution Amid Disruption and Raises 2025 Profit Guidance
In his first earnings call as CEO, Derek Duke emphasized a deliberate and optimistic approach to the 2025 Medicare Annual Enrollment Period (AEP), highlighting eHealth’s strong position amidst ongoing...
- New CEO Derek Duke spotlights AEP execution as top priority, seeing massive opportunity in Medicare advantage and adjacent markets.
- Q3 2025 revenue fell 8% year-over-year to $53.9 million, impacted notably by new dual-eligible enrollment rules reducing Medicare volume.
- Positive net adjustment (TEL) revenue of $12.1 million in Q3 significantly boosted profitability relative to prior year.
- +10 more takeaways
CS Disco Q3 2025 Earnings Call - Accelerated Growth Fueled by AI and Strategic Customer Focus
CS Disco reported strong Q3 fiscal 2025 results, delivering 17% software revenue growth year-over-year and 13% total revenue growth, surpassing guidance despite a one-time $1.3 million contingent reve...
- Q3 software revenue rose 17% year-over-year to $35.2 million, total revenue grew 13% to $40.9 million, beating guidance.
- Included $1.3 million contingent revenue from a successful legal case; without it, growth still exceeded guidance.
- Adjusted EBITDA improved substantially to negative $0.3 million, a $4.2 million year-over-year improvement, with margins nearing break-even at -1%.
- +13 more takeaways
Miami International Holdings Q3 2025 Earnings Call - Record Market Share and Strong Post-IPO Growth
Miami International Holdings (MIAX) posted a robust Q3 2025 with net revenues soaring 57% year over year to a record $109.5 million, led by a surging options business and rising market share. Their mu...
- MIAX achieved 57% year-over-year net revenue growth to a record $109.5 million in Q3 2025.
- Multi-listed options market share reached a record 17.2%, up 24% from prior year, with October further increasing to 19.4%.
- Strong industry options volume growth driven by elevated volatility and retail participation supported results.
- +9 more takeaways
Veeco Q3 2025 Earnings Call - Strong execution beats guidance as merger with Accellis promises market expansion
Veeco reported robust Q3 2025 results with revenue at $166 million, surpassing the guidance midpoint, and non-GAAP EPS of $0.36, highlighting strong execution and operational discipline amid sustained...
- Q3 2025 revenue reached $166 million, exceeding guided midpoint of $160 million.
- Non-GAAP diluted EPS was $0.36, above the guided midpoint of $0.28 due to strong operational execution.
- Veeco announced a definitive merger agreement with Accellis Technologies to create a leading semiconductor equipment company.
- +17 more takeaways
IonQ Q3 2025 Earnings Call - Quantum Platform Leadership Drives Record Revenue and Historic Technical Breakthroughs
IonQ's Q3 2025 quarter was transformative, delivering its largest-ever revenue beat, exceeding guidance by 37%, with 222% year-over-year growth reaching $39.9 million. The company advanced its full-st...
- IonQ reported Q3 2025 revenues of $39.9 million, a 222% increase year-over-year, exceeding high-end guidance by 37%, marking its largest quarterly revenue beat ever.
- The AQ64 Tempo system, IonQ's fifth-generation quantum computer, was completed three months ahead of schedule, expanding computational space 260 million times compared to the Forte system.
- IonQ achieved a historic 99.99% two-qubit gate fidelity, the first company to hit all key technical milestones for full fault tolerance quantum computing scale.
- +13 more takeaways
Jazz Pharmaceuticals 2025 Third Quarter Earnings Call - Record Revenues and Strategic Pipeline Milestones Fuel Confidence Amid Upcoming Generic Challenges
Jazz Pharmaceuticals closed Q3 2025 with its strongest quarter ever, surpassing $1.1 billion in revenues, powered by key products like Xywav, Epidiolex, and the fast launch of Modeso. The company secu...
- Jazz Pharmaceuticals reported its highest-ever quarterly revenue of $1.126 billion in Q3 2025, driven by strong sales of Xywav, Epidiolex, and the accelerated launch of Modeso.
- FDA approvals for Modeso and expanded Zepzelca indication (combined with Tecentriq for first-line maintenance in extensive-stage small cell lung cancer) underscore Jazz's robust pipeline and commercial execution.
- Xywav net sales grew 11% year-over-year to $431 million, with continued patient adds and strong differentiation as the only low-sodium oxybate, critical ahead of expected generic entry for high-sodium Xyrem in 2026.
- +7 more takeaways
Fortinet Q3 2025 Earnings Call - SaaS Growth Surges While Service Revenue Trails, Backed by Unified Security Platform
Fortinet delivered strong Q3 2025 results with 14% growth in billings and revenue, led by a staggering 100% increase in Fortinet SaaS billings. The company highlighted its unique FortiOS single operat...
- Fortinet’s billings and revenue each grew 14% year-over-year in Q3 2025, demonstrating broad-based demand.
- Fortinet SaaS billings more than doubled (100%+ growth), marking the company as one of the fastest-growing SaaS players at scale.
- The FortiOS single operating system uniquely integrates firewall, SD-WAN, and SaaS functions in one platform for easy upsell and deployment.
- +12 more takeaways
Cytokinetics Q3 2025 Earnings Call - Aficamten Launch Readiness Peaks Amid Regulatory Milestones
Cytokinetics delivered a pivotal quarter focused on commercial and regulatory preparation for Aficamten, targeting potential U.S. FDA approval by year-end 2025 and EMA decision by mid-2026. Key clinic...
- Cytokinetics expects potential FDA approval of Aficamten for OHCM by end of 2025, with EMA decision anticipated in first half of 2026.
- Positive Phase 3 Maple HCM trial results demonstrated Aficamten's superiority over metoprolol, challenging current beta-blocker treatment paradigms.
- The company completed all FDA GCP inspections with no observations and does not anticipate pre-approval inspections, indicating regulatory confidence.
- +7 more takeaways